Myeloprotection with drug-resistance genes

被引:18
作者
Banerjee, D
Bertino, JR
机构
[1] Molecular Pharmacology and Experimental Therapeutics Program, Sloan Kettering Institute for Cancer Research, New York, NY
[2] Departments of Medicine and Pharmacology, Robert Wood Johnson Medical School
[3] Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903
关键词
D O I
10.1016/S1470-2045(02)00678-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One of the many applications of gene transfer for cancer gene therapy is the transfer of drug-resistance genes into bone-marrow stem cells for myeloprotection. Protection of the hosts' bone marrow should allow for dose escalation that may be useful for eradicating minimal residual disease in a post-transplant situation. A number of drug resistance genes, whose products include mutant forms of enzymes that confer resistance to chemotherapeutic drugs, are discussed. Advances in hematopoietic stem cell isolation and ex vivo manipulation has kept pace with improvements in retroviral vector technology to make hematopoietic stem cell transduction a distinct reality. Clinical trials, which have established that the approach is safe, are now being designed to address more therapeutically relevant issues.
引用
收藏
页码:154 / 158
页数:5
相关论文
共 55 条
[1]   Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells [J].
Abonour, R ;
Williams, DA ;
Einhorn, L ;
Hall, KM ;
Chen, J ;
Coffman, J ;
Traycoff, CM ;
Bank, A ;
Kato, I ;
Ward, M ;
Williams, SD ;
Hromas, R ;
Robertson, MJ ;
Smith, FO ;
Woo, D ;
Mills, B ;
Srour, EF ;
Cornetta, K .
NATURE MEDICINE, 2000, 6 (06) :652-658
[2]   In vivo selection of retrovirally transduced hematopoietic stem cells [J].
Allay, JA ;
Persons, DA ;
Galipeau, J ;
Riberdy, JM ;
Ashmun, RA ;
Blakley, RL ;
Sorrentino, BP .
NATURE MEDICINE, 1998, 4 (10) :1136-1143
[3]   GENE-THERAPY UTILIZING DRUG-RESISTANCE GENES - A REVIEW [J].
BANERJEE, D ;
ZHAO, SC ;
LI, MX ;
SCHWEITZER, BI ;
MINEISHI, S ;
BERTINO, JR .
STEM CELLS, 1994, 12 (04) :378-385
[4]  
BARBOUR KW, 1990, MOL PHARMACOL, V37, P515
[5]   TURNING THE TABLES - MAKING NORMAL MARROW RESISTANT TO CHEMOTHERAPY [J].
BERTINO, JR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (15) :1234-1235
[6]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[7]  
Blakley RL, 1998, HUM MUTAT, V11, P259, DOI 10.1002/(SICI)1098-1004(1998)11:4<259::AID-HUMU1>3.0.CO
[8]  
2-W
[9]   Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo [J].
Boczkowski, D ;
Nair, SK ;
Snyder, D ;
Gilboa, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) :465-472
[10]   Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice [J].
Bunting, KD ;
Galipeau, J ;
Topham, D ;
Benaim, E ;
Sorrentino, BP .
BLOOD, 1998, 92 (07) :2269-2279